$110.75 $0.20 (0.2%)

04:00 PM EST on 12/13/19

Spark Therapeutics, Inc. (NASDAQ:ONCE)

CAPS Rating: 4 out of 5

Current Price $110.75 Mkt Cap $4.3B
Open $110.57 P/E Ratio 0.00
Prev. Close $110.55 Div. (Yield) $0.00 (0.0%)
Daily Range $110.02 - $111.30 Volume 770,383
52-Wk Range $37.77 - $114.20 Avg. Daily Vol. 543,751

Caps

How do you think NASDAQ:ONCE will perform against the market?

Add Stock to CAPS Watchlist

All Players

53 Outperform
3 Underperform
 

All-Star Players

22 Outperform
1 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:ONCE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFSaintCroix (99.33)
Submitted December 23, 2017

The FDA has just approved their drug for a rare form of blindness. It's the first gene therapy for a genetic disease in human history. The price the company is talking about charging for this drug is $1 million dollars. And the reason they are… More

TSIF (99.97)
Submitted October 05, 2015

WARNING: BIOPHARMS on "news", (testing results, approvals) can overshoot, drop and climb much higher as shorts / speculators jockey with day traders to open and close positions... my thumbing is based on past patterns and the only rule I have about… More

NASDAQ:ONCE VS S&P 500 (SPY)

NASDAQ:ONCE Summary

Fools bullish on NASDAQ:ONCE are also bullish on:

Fools bearish on NASDAQ:ONCE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ONCE.

Recs

0
Member Avatar TMFBigFrog (94.61) Submitted: 6/2/2018 10:46:49 AM : Outperform Start Price: $80.78 NASDAQ:ONCE Score: +21.52

One recent approval and the potential for more. The adeno-associated virus vector it uses has shown success and looks promising for future therapies.

Recs

0
Member Avatar TMFEBCapital (85.43) Submitted: 12/7/2017 1:31:38 PM : Outperform Start Price: $71.02 NASDAQ:ONCE Score: +35.87

Gene therapy could revolutionize hemophilia A and B treatment for 130,000+ patients, removing the need for prophylactic infusions of missing clotting factor and eliminating or reducing the risk of life-threatening hemorrhages.

Recs

0
Member Avatar sullyz0r (65.54) Submitted: 5/28/2015 11:24:30 AM : Outperform Start Price: $68.57 NASDAQ:ONCE Score: +11.95

Closing out bluebird and adding spark to replace. Bluebird's getting a bit crazy for me here, and sold in real life. Probably will miss out on thousands, but it's too early and frothy. ONCE isn't much less frothy, but it's all relative, right?

Leaderboard

Find the members with the highest scoring picks in ONCE.

Score Leader

paullng

paullng (< 20) Score: +319.61

The Score Leader is the player with the highest score across all their picks in ONCE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
paullng < 20 2/10/2016 Outperform 3Y $22.61 +389.83% +70.22% +319.61 0 Comment
portefeuille 98.39 2/10/2016 Outperform 5Y $23.30 +375.32% +69.01% +306.32 0 Comment
dollarsandcents1 < 20 4/6/2016 Outperform 5Y $32.29 +242.99% +55.32% +187.67 0 Comment
jeepdrew222 69.57 5/16/2016 Outperform 5Y $33.77 +227.95% +54.81% +173.14 0 Comment
NextGenStock < 20 2/8/2019 Outperform 5Y $46.47 +138.33% +18.07% +120.26 0 Comment
drugtrader 93.18 10/8/2018 Outperform 5Y $48.45 +128.59% +10.54% +118.05 0 Comment
IamaFOOL2 83.49 12/18/2017 Outperform 5Y $47.02 +135.54% +18.35% +117.19 0 Comment
jettyjett 65.17 1/4/2016 Outperform 5Y $41.33 +167.97% +58.66% +109.31 0 Comment
Dima 93.36 1/16/2018 Outperform 5Y $49.79 +122.44% +13.86% +108.59 0 Comment
stainsolution < 20 12/20/2017 Outperform 5Y $50.19 +120.66% +18.28% +102.39 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ONCE.